報價延遲最少15分鐘:2025/09/18 06:08 EDT
盤前時段
|
||||
|
6.31 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.21
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.20/-3.20
|
|
企業價值
113.72M
|
| 資產負債 |
|
每股賬面淨值
0.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
71.32M
|
|
每股收益
5.50
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/18 06:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
